SQI Diagnostics Inc. announced it has signed a revenue-producing agreement with a global biotechnology company to provide assay development and future sample testing and analysis services.
This customer has contracted test development to SQI to create an immunogenicity assay utilizing SQI’s multiplexing technology. After completing test development, SQI anticipates it will be engaged to provide contract research services to provide analytical sample testing. This testing will be done at SQI’s state-of-the-art facility in Toronto. This contract research service augments SQI’s product offerings enabling pharma and biotech customers to outsource their multiplexed assay development, validation, and testing services to SQI.
“The new customer is a global US-based biotechnology company that develops new drug treatments for patients with serious rare diseases,” said Andrew Morris, CEO of SQI Diagnostics. “This is the latest in a growing list of customers to engage SQI’s newest and fastest-growing business: contract testing services. In the past 12 months alone, SQI has done 6 revenue-producing deals, with companies ranging from diagnostic companies, to global pharmaceutical and biotechnology companies.”
